U.S. Markets close in 4 hrs 56 mins

DexCom, Inc. (DXCM)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
312.55-0.77 (-0.25%)
As of 4:00PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close313.32
Bid311.51 x 1000
Ask315.90 x 3000
Day's Range311.01 - 320.14
52 Week Range182.07 - 456.23
Avg. Volume1,041,950
Market Cap30.013B
Beta (5Y Monthly)0.95
PE Ratio (TTM)129.21
EPS (TTM)2.42
Earnings DateFeb 11, 2021 - Feb 15, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est462.94
  • DexCom Could Work Itself Lower in the Weeks Ahead

    DexCom Could Work Itself Lower in the Weeks Ahead

    During the ever popular Mad Money Lightning Round Tuesday evening one caller asked Jim Cramer about DexCom . "There's competition coming from Medtronic and people need to get more careful," replied Cramer. In the updated daily bar chart of DXCM, below, we can see that the shares have been in a decline the past four months now.

  • Could DexCom Be a Millionaire-Maker Stock?
    Motley Fool

    Could DexCom Be a Millionaire-Maker Stock?

    Between its life-changing continuous glucose monitors, consistent growth, and sound fundamentals, DexCom (NASDAQ: DXCM) has many of the hallmarks of a good investment. It's unlikely because the stock won't be experiencing triple-digit growth anytime soon. DexCom's wearable continuous glucose monitoring (CGM) products help people with diabetes to manage their conditions without the pain of repeatedly pricking their fingers to take glucose measurements from droplets of blood.

  • These 3 Medical Device Stocks Leave Biotech in the Dust
    Motley Fool

    These 3 Medical Device Stocks Leave Biotech in the Dust

    When it comes to consistent profitability, long-term growth, large competitive moats, and innovation, medical device companies can provide better returns in the long run. In particular, DexCom (NASDAQ: DXCM), Medtronic (NYSE: MDT), and Abiomed (NASDAQ: ABMD) have beaten the NASDAQ Biotechnology Index handily over the last five years. If you had to check your blood glucose level a few times per day, you'd probably grow tired of pricking your finger to draw a drop of blood.